If the Aim Is to Lower Drug Prices, Who Is in the Crosshairs?

Share this post

Many entities’ opaque practices have led to criticism that businesses — from manufacturers to insurers to pharmacy benefit managers — are pocketing savings that should be accruing to patients.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply